← Back to screener

DiaMedica Therapeutics Inc. DMAC

Rank #2223 · Nasdaq · $0.5B market cap
Audited by Baker Tilly US, LLP, no going-concern flag in the latest filing.
Score
28.6
P/E
-20.4
P/B
9.76
ROE
-47.9%
Op. Margin
–%
Debt Ratio
-9%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -20.4x, P/B 9.76x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -47.9%. Ranks in the top 88% of the universe.

Safety ★★★★★
Excellent

Debt ratio -9%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.0B$-0.0B$-0.0B$0.0B-903.862
2019$0.0B$-0.0B$-0.0B$0.0B-1352.22195
2020–$-0.0B$-0.0B$0.0B–-47
2021–$-0.0B$-0.0B$0.0B–269
2022–$-0.0B$-0.0B$0.0B–75
2023–$-0.0B$-0.0B$0.0B–-22
2024–$-0.0B$-0.0B$0.0B–70
2025–$-0.0B$-0.0B$0.1B–-9

← See the full screener